These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29314498)

  • 1. Design of Aminobenzothiazole Inhibitors of Rho Kinases 1 and 2 by Using Protein Kinase A as a Structure Surrogate.
    Judge RA; Vasudevan A; Scott VE; Simler GH; Pratt SD; Namovic MT; Putman CB; Aguirre A; Stoll VS; Mamo M; Swann SI; Cassar SC; Faltynek CR; Kage KL; Boyce-Rustay JM; Hobson AD
    Chembiochem; 2018 Mar; 19(6):613-621. PubMed ID: 29314498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors.
    Yin Y; Lin L; Ruiz C; Cameron MD; Pocas J; Grant W; Schröter T; Chen W; Duckett D; Schürer S; Lograsso P; Feng Y
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6686-90. PubMed ID: 19837589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.
    Bandarage UK; Cao J; Come JH; Court JJ; Gao H; Jacobs MD; Marhefka C; Nanthakumar S; Green J
    Bioorg Med Chem Lett; 2018 Aug; 28(15):2622-2626. PubMed ID: 30082069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological characterization of selective LIMK inhibitors.
    Boland S; Bourin A; Alen J; Geraets J; Schroeders P; Castermans K; Kindt N; Boumans N; Panitti L; Vanormelingen J; Fransen S; Van de Velde S; Defert O
    Bioorg Med Chem Lett; 2015 Sep; 25(18):4005-10. PubMed ID: 26233434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups.
    Gao H; Marhefka C; Jacobs MD; Cao J; Bandarage UK; Green J
    Bioorg Med Chem Lett; 2018 Aug; 28(15):2616-2621. PubMed ID: 29945794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROCK inhibitors 4: Structure-activity relationship studies of 7-azaindole-based rho kinase (ROCK) inhibitors.
    Bandarage UK; Court J; Gao H; Nanthakumar S; Come JH; Giroux S; Green J
    Bioorg Med Chem Lett; 2021 Feb; 33():127721. PubMed ID: 33259926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of 5H-chromeno[3,4-c]pyridine and 6H-isochromeno[3,4-c]pyridine derivatives as potent and selective dual ROCK inhibitors.
    Hu Z; Wang C; Sitkoff D; Cheadle NL; Xu S; Muckelbauer JK; Adam LP; Wexler RR; Quan ML
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127474. PubMed ID: 32805407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.
    Green J; Cao J; Bandarage UK; Gao H; Court J; Marhefka C; Jacobs M; Taslimi P; Newsome D; Nakayama T; Shah S; Rodems S
    J Med Chem; 2015 Jun; 58(12):5028-37. PubMed ID: 26039570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension.
    Shaw D; Hollingworth G; Soldermann N; Sprague E; Schuler W; Vangrevelinghe E; Duggan N; Thomas M; Kosaka T; Waters N; van Eis MJ
    Bioorg Med Chem Lett; 2014 Oct; 24(20):4812-7. PubMed ID: 25248678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a phenylpyrazole amide ROCK inhibitor as a tool molecule for in vivo studies.
    Hu Z; Wang C; Glunz PW; Li J; Cheadle NL; Chen AY; Chen XQ; Myers JE; Guarino VR; Rose A; Sack JS; Sitkoff D; Taylor DS; Xu S; Yan C; Zhang H; Zhang L; Hennan J; Adam LP; Wexler RR; Quan ML
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127495. PubMed ID: 32798651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological evaluation of 4-aryl-5-aminoalkyl-thiazole-2-amines derivatives as ROCK II inhibitors.
    Ma S; Wang L; Ouyang B; Fan M; Qi J; Yao L
    Bioorg Med Chem; 2020 Oct; 28(19):115683. PubMed ID: 32912437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review on ROCK-II inhibitors: From molecular modelling to synthesis.
    Shah S; Savjani J
    Bioorg Med Chem Lett; 2016 May; 26(10):2383-2391. PubMed ID: 27080184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and biological evaluation of urea-based ROCK2 inhibitors.
    Wang L; Qi J; Fan M; Yao L
    Chem Biol Drug Des; 2021 Dec; 98(6):969-978. PubMed ID: 34581498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization and biological evaluation of 2-aminobenzothiazole derivatives as Aurora B kinase inhibitors.
    Lee E; An Y; Kwon J; Kim KI; Jeon R
    Bioorg Med Chem; 2017 Jul; 25(14):3614-3622. PubMed ID: 28529042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma.
    Abbhi V; Saini L; Mishra S; Sethi G; Kumar AP; Piplani P
    Bioorg Med Chem; 2017 Nov; 25(21):6071-6085. PubMed ID: 29033348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors.
    Guan R; Xu X; Chen M; Hu H; Ge H; Wen S; Zhou S; Pi R
    Eur J Med Chem; 2013; 70():613-22. PubMed ID: 24211637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK).
    MacKinnon CH; Lau K; Burch JD; Chen Y; Dines J; Ding X; Eigenbrot C; Heifetz A; Jaochico A; Johnson A; Kraemer J; Kruger S; Krülle TM; Liimatta M; Ly J; Maghames R; Montalbetti CA; Ortwine DF; Pérez-Fuertes Y; Shia S; Stein DB; Trani G; Vaidya DG; Wang X; Bromidge SM; Wu LC; Pei Z
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6331-5. PubMed ID: 24138940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo optimization of 2,3-diaminopyrazine Rho Kinase inhibitors for the treatment of glaucoma.
    Chen HH; Namil A; Severns B; Ward J; Kelly C; Drace C; McLaughlin MA; Yacoub S; Li B; Patil R; Sharif N; Hellberg MR; Rusinko A; Pang IH; Combrink KD
    Bioorg Med Chem Lett; 2014 Apr; 24(8):1875-9. PubMed ID: 24684843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of potential Rho-kinase inhibitors based on the chemistry of an original heterocycle: 4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one.
    Letellier MA; Guillard J; Caignard DH; Ferry G; Boutin JA; Viaud-Massuard MC
    Eur J Med Chem; 2008 Aug; 43(8):1730-6. PubMed ID: 18164518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substituted 2-arylbenzothiazoles as kinase inhibitors: hit-to-lead optimization.
    Tasler S; Müller O; Wieber T; Herz T; Pegoraro S; Saeb W; Lang M; Krauss R; Totzke F; Zirrgiebel U; Ehlert JE; Kubbutat MH; Schächtele C
    Bioorg Med Chem; 2009 Sep; 17(18):6728-37. PubMed ID: 19692247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.